Following is based on info from broker presentations and various...

Following is based on info from broker presentations and various posts on HC...

We are waiting on 3 announcements:

1. Conclusion of Hep E deal with Genelabs following due diligence. Deal expected to be worth approx $700K per year in revenue.

2. Hep A deal progress, given that SLT went to Europe and UK and met with 6-8 potential companies interested in the Hep A rapid diagnostic kit. Deal expected to be concluded by March 04. Deal expected to be worth 5x Hep E - so say $3m

3. Collaboration announcement to rapidly develop Hep C with a major US biotech that wants rights to sell the kit when ready. Expected deal size - BIG but no figures given yet. Expect at least $10m per year.

All of these are expected in November.

If SLT pulls off all of the above, given modest exps of $1.5m per year, the company could easily be worth $100m (6 times current market cap around $16m). Note that CST, another company in daignostics, has revenues around $1m and a market cap of over $100m (mind you I have not looked into CST's prospects).

Good luck.